PP13, maternal ABO blood groups and the risk assessment of pregnancy complications Academic Article uri icon

abstract

  • Background: Placental Protein 13 (PP13), an early biomarker of preeclampsia, is a placenta-specific galectin that binds betagalactosides, building-blocks of ABO blood-group antigens, possibly affecting its bioavailability in blood. Methods and Findings: We studied PP13-binding to erythrocytes, maternal blood-group effect on serum PP13 and its performance as a predictor of preeclampsia and intrauterine growth restriction (IUGR). Datasets of maternal serum PP13 in Caucasian (n=1078) and Hispanic (n=242) women were analyzed according to blood groups. In vivo, in vitro and in silico PP13-binding to ABO blood-group antigens and erythrocytes were studied by PP13-immunostainings of placental tissuemicroarrays, flow-cytometry of erythrocyte-bound PP13, and model-building of PP13 - blood-group H antigen complex, respectively. Women with blood group AB had the lowest serum PP13 in the first trimester, while those with blood group B had the highest PP13 throughout pregnancy. In accordance, PP13-binding was the strongest to blood-group AB erythrocytes and weakest to blood-group B erythrocytes. PP13-staining of maternal and fetal erythrocytes was revealed, and a plausible molecular model of PP13 complexed with blood-group H antigen was built. Adjustment of PP13 MoMs to maternal ABO blood group improved the prediction accuracy of first trimester maternal serum PP13 MoMs for preeclampsia and IUGR. Conclusions: ABO blood group can alter PP13-bioavailability in blood, and it may also be a key determinant for other lectins’ bioavailability in the circulation. The adjustment of PP13 MoMs to ABO blood group improves the predictive accuracy of this test.

publication date

  • January 1, 2011